4568 On Other Exchanges
Symbol
Exchange
4568 is not on other exchanges.

daiichi sankyo co ltd (4568) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DAIICHI SANKYO CO LTD (4568)

Related News

No related news articles were found.

daiichi sankyo co ltd (4568) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (4568) Details

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. The company’s generic pharmaceuticals include olmesartan, azelnidipine, and amlodipine antihypertensive agents; loxoprofen, an anti-inflammatory analgesic; levofloxacin, a synthetic antibacterial agent; esomeprazole for ulcer treatment; memantine and donepezil for treating alzheimer’s disease; pravastatin and atorvastatin antihyperlipidemic agents; carvedilol for treating hypertension, angina pectoris, and chronic heart failure; iohexol to enhance visibility of diagnostic X-ray imaging; silodosin for treating dysuria; laninamivir for anti-influenza treatment; edoxaban, an anticoagulant; teneligliptin and pioglitazone type 2 diabetes mellitus inhibitors; denosumab for treating bone complications; denosumab for treating osteoporosis; and prasugrel, an antiplatelet agent. Its generic pharmaceuticals also comprise colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus indication, as well as iron sucrose and ferric carboxymaltose injections for treating anemia. The company also provides over the counter products, such as Lulu, combination cold remedy; Daiichi Sankyo Ichoyaku, a multi-ingredient digestive remedy; Loxonin S, an antipyretic analgesic; Patecs, an antiphlogistic analgesic for external use; and Transino for treating melisma. In addition, it offers ActHIB, a haemophilus influenzae type b vaccine; Rotarix, a rotavirus vaccine; Influenza HA Vaccine; and Live Attenuated Measles/Rubella Combined Vaccine. Further, it manufactures and sells cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates, as well as pharmaceuticals and drugs for animals. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

15,249 Employees
Last Reported Date: 06/20/16
Founded in 1899

daiichi sankyo co ltd (4568) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥140.0M
Compensation as of Fiscal Year 2016.

daiichi sankyo co ltd (4568) Key Developments

Amgen and Daiichi Sankyo Company Limited Announce Agreement to Commercialize Biosimilars in Japan

Amgen and Daiichi Sankyo Company Limited announced the execution of an exclusive agreement to commercialize nine biosimilars in Japan. The deal includes several biosimilars in late-stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab. Under the terms of the agreement, Amgen will remain responsible for the development and manufacturing of the biosimilars. Daiichi Sankyo will file for marketing approval and be responsible for distribution and commercialization in Japan, while Amgen will have a limited right to co-promote the products. Amgen will retain all additional distribution and commercialization rights for the biosimilar programs outside of Japan. Specific financial terms of the agreement were not disclosed.

Daiichi Sankyo Company, Limited and UCB Biopharma SPRL Announce Japanese Approval of Lacosamide as Adjunctive Therapy in the Treatment of Partial-Onset Seizures in Adult Patients with Epilepsy

Daiichi Sankyo Company, Limited and UCB Biopharma SPRL announced the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted approval for lacosamide (brand name VIMPAT) as an adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adult patients with epilepsy who have not obtained sufficient response to other antiepileptic drugs. DaiichiSankyo and UCB will partner to commercialize lacosamide in Japan, as agreed previously by both companies in 2014. UCB will manufacture and supply the product; Daiichi Sankyo will manage distribution and book sales in Japan, with both companies promoting lacosamide in Japan.

Servier Canada Enters into Agreement with Daiichi Sankyo Co., Limited for Factor Xa Inhibitor Edoxaban

Servier Canada announced the signing of a strategic agreement with Daiichi Sankyo Co., Limited. Under this agreement, Servier will commercialize the oral, once-daily anti-coagulant Edoxaban in Canada, if approved by the Canadian health authority, while Daiichi Sankyo will receive an upfront payment, regulatory and sales milestones payments as well as royalties on net product sales. Edoxaban is a novel anti-coagulant treatment that specifically inhibits factor Xa of the coagulation pathway, highly involved in blood clotting. Edoxaban is currently under review by Health Canada for the prevention of stroke and systemic embolic events in patients with non valvular atrial fibrillation, as well as for the treatment of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, and the prevention of recurrent VTE. This current filing is based on a worldwide clinical development program that includes two large phase III pivotal trials, Hokusai-VTE and ENGAGE AF-TIMI 48. Estimations claim that non valvular atrial fibrillation affects about 350,000 Canadians, a number that is expected to increase as the population ages1, and that VTE affects up to 45,000 Canadians per year. Edoxaban has been approved in the U.S. as SAVAYSA® and in the EU, Switzerland, Japan, South Korea, Taiwan and Hong Kong as LIXIANA®. This contract is in line with Servier's leading role in efficient treatments for cardiovascular diseases, an area where the Group has always shown a strong expertise.

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4568 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4568.
View Industry Companies
 

Industry Analysis

4568

Industry Average

Valuation 4568 Industry Range
Price/Earnings 22.6x
Price/Sales 1.9x
Price/Book 1.5x
Price/Cash Flow 23.2x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DAIICHI SANKYO CO LTD, please visit www.daiichisankyo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.